Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Jul 21, 2014; 20(27): 8947-8956
Published online Jul 21, 2014. doi: 10.3748/wjg.v20.i27.8947
Table 1 Current recommendations for Helicobacter pylori eradication
TreatmentRegion with low clarithromycin prevalenceRegion with high clarithromycin prevalence
First linePPI - clarithromycin - amoxicillin/metronidazole or bismuth quadrupleBismuth quadruple1. If not available: non-bismuth quadruple (either sequential or concomitant)
Second lineBismuth quadruple1 or PPI - levofloxacin/amoxicillinPPI - levofloxacin/amoxicillin
Third lineBased on susceptibility testing only. Besides clarithromycin and levofloxacin, rifabutin is another candidate that may be used
Table 2 Randomized controlled trials containing levofloxacin in first-line triple therapy of Helicobacter pylori
Ref.YearNationPatientsTherapyPosologyDurationComparatorITT
Shah et al[53]2013India131LTE500785.0%
Qian et al[54]2012China345LAE5007SEQ-L78.1%
Cuadrado-Lavín et al[61]2012Spain250LAO50010CAO82.8%
Pan et al[62]2010China199LAE5007NAR87.1%
Chen et al[63]2010Taiwan189LCE5007CAE78.9%
Assem et al[64]2010Egypt450LAE5007CLE/CAE84.7%
Erçin et al[65]2010Turkey91LAL50014LAL (7)72.0%
Liou et al[66]2010Taiwan432LAL5007CAL74.0%
Chen et al[63]2010China300LAL5007CAL74.0%
Molina-Infante et al[69]2010Spain460LAO50010SEQ-L82.6%
Castro-Fernández et al[59]2009Spain135LAO5001071.8%
Gisbert et al[55]2007Spain64LARBIS5001084.4%
Rispo et al[52]2007Italy130LAE5007CAE90.8%
Nista et al[51]2006Italy300CLE5007CME/CAE87.0%
Lee et al[56]2006South Korea267LAE5007CAE69.8%
Cammarota[50]2004Italy100CLR5007CLR (250)84.0%